Patent intelligence · US
US 6413523
Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
Patent details — US 6413523
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 2, 2002
- Expiration
- Jun 27, 2022
- Claims
- 18
- CPC classes
- A61K, A61K2039/55544, A61K39/39
Quick answer
US 6413523 (Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use) is held by United States of America as represented by the Secretary of the Air Force. Status: expired. Granted Jul 2, 2002. Expires Jun 27, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/55544, A61K39/39
More from United States of America as represented by the Secretary of the Air Force
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 6413523?
US 6413523 (Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use) is held by United States of America as represented by the Secretary of the Air Force. Status: expired. Granted Jul 2, 2002. Expires Jun 27, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6413523?
United States of America as represented by the Secretary of the Air Force is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 6413523 expire?
Our index shows an expiration date of Jun 27, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.